NasdaqGS:EWTXPharmaceuticals
Assessing Edgewise Therapeutics (EWTX) Valuation After Strong Multi Year Shareholder Returns
Recent share performance and business context
Edgewise Therapeutics (EWTX) has drawn investor attention after a mixed stretch in the stock, with the price down about 9% over the past month but up roughly 4% over the past 3 months.
Over longer periods, the stock shows a year to date gain of about 32% and a 1 year total return a little above 111%, alongside a 3 year total return a little above 224%, on a market value near US$3.4b.
The company focuses on therapies for muscle disorders, with lead...